Please wait while the formulary information is being retrieved.
WELIREG (belzutifan)
- neoplasm associated with von Hippel-Lindau disease
40 mg tablet
- 3 tablets (120 mg) by oral route once daily
Default screening record
- 1 tablet (40 mg) by oral route once daily
- 2 tablets (80 mg) by oral route once daily
- 3 tablets (120 mg) by oral route once daily
- None
Contraindicated
- bedaquiline
- Bosulif
- bosutinib
- guanfacine
- Intuniv Er
- Olysio
- simeprevir
- Sirturo
- Tenex
Severe
Moderate
- None
- Lactation
Contraindicated
- Anemia
- Hypoxia
- Pregnancy
Severe
Moderate
- None
WELIREG (belzutifan)
- neoplasm associated with von Hippel-Lindau disease
- Anemia
- Dizziness
- Fatigue
- Headache disorder
- Nausea
More Frequent
Severe
Less Severe
- Hypertension
- Hypocalcemia
- Hypophosphatemia
- Hypoxia
- Increased alanine transaminase
- Increased aspartate transaminase
- Acute abdominal pain
- Arthralgia
- Constipation
- Dyspnea
- Flu-like symptoms
- Myalgia
- Upper respiratory infection
- Visual changes
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Dehydration
Less Severe
- Cough
- Diarrhea
- Edema
- Musculoskeletal pain
- Vomiting
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Belzutifan
Safety and effectiveness not established for pediatric patients.
- 1 Day – 18 Years
- Safety and effectiveness not established for pediatric patients.
Belzutifan
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Belzutifan
Manufacturer does not rec during treatment and for 1 week after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Manufacturer does not rec during treatment and for 1 week after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Tell your doctor if you are pregnant or plan to become pregnant. Your doctor may order a pregnancy test before starting this medication. You should not become pregnant while using belzutifan.<br /><br />Belzutifan may harm an unborn baby. Women of childbearing age should ask about reliable non-hormonal forms of birth control while using this medication and for 1 week after the last dose. Men with female partners of childbearing age should use reliable forms of birth control while using this medication and for 1 week after the last dose. If you or your partner becomes pregnant, talk to your doctor right away about the risks and benefits of this medication.
| Neoplasm associated with von hippel-lindau disease | |
| Q85.8 | Other phakomatoses, not elsewhere classified |
| Q85.83 | Von hippel-lindau syndrome |
| Q85.89 | Other phakomatoses, not elsewhere classified |
| Renal cell carcinoma | |
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| 0-9 | A-Z |
|---|---|
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| Q85.8 | Other phakomatoses, not elsewhere classified |
| Q85.83 | Von hippel-lindau syndrome |
| Q85.89 | Other phakomatoses, not elsewhere classified |
Formulary Reference Tool